Christine Chen Princess Margaret Cancer Centre September 2013
|
|
- Conrad Wilkinson
- 5 years ago
- Views:
Transcription
1 Christine Chen Princess Margaret Cancer Centre September 2013
2 Disclosures Research Support Celgene, Janssen, GSK Employee N/A Consultant N/A Major Stockholder Speakers Bureau/ Scientific Advisory Board N/A Celgene, Janssen, Lundbeck, Roche
3 Objec.ves Review the data supporting the use of maintenance in myeloma Post-transplant and transplant-ineligible patients Using thalidomide, lenalidomide, bortezomib Issues selection, toxicities, logistics
4 Maintenance Therapy Description Ideal characteristics Goal Endpoint Prolonged duration Low intensity Often single agent Minimal longterm, cumulative toxicity Convenient (oral) Cheap Stabilization and ongoing control of disease (not necessarily aiming to improve quality of response) PFS/EFS, TTP, TTNT, DOR (OS)
5 Maintenance Therapy in MM Phase 3 trials Post- transplant o Thalidomide 7 trials (thalidomide +/- steroids) o Lenalidomide IFM (consolida>on and maintenance) CALGB o Bortezomib Hovon MM 65/GMMG- HD4 (btz alone) Following non- transplant therapy o Thalidomide o 4 RCTs comparing MPT vs MP used thalidomide maintenance o CEMSG thal + IFN o MRC IX thal alone o Lenalidomide MM- 015 (MPR- R) o Bortezomib GIMEMA (VT following VMP- VT) PETHEMA (VT vs VP)
6 Maintenance Therapy in MM Phase 3 trials Post- transplant o Thalidomide 7 trials (thalidomide +/- steroids) o Lenalidomide IFM (consolida>on and maintenance) CALGB o Bortezomib Hovon MM 65/GMMG- HD4 (btz alone) Following non- transplant therapy o Thalidomide o 4 RCTs comparing MPT vs MP used thalidomide maintenance o CEMSG thal + IFN o MRC IX thal alone o Lenalidomide MM- 015 (MPR- R) o Bortezomib GIMEMA (VMPT- VT)
7 Thalidomide maintenance after ASCT Author (year) N Thalidomide dose (mg) / duration PFS / EFS OS Attal (2006) 597 Thal 200mg (med) vs obs / until PD + + Spencer (2006) 243 Thal 200mg + pred vs pred / 12 months + + Maiolino (2008) 212 Thal 200mg + dex vs dex / 12 months + NS Barlogie (2006) 668 Thal 400mg / until PD + NS, + in hi-risk Morgan (2012) - Thal mg / until PD +/- NS Lockhorst (2010) 550 Thal 50mg / until PD + - Stewart (2010) 325 Thal 200mg + pred vs obs / 48 months + NS Thalidomide maintenance in non-asct patients Author (year) N Thalidomide dose (mg), duration PFS / EFS OS Palumbo (2008) 331 Thal 100mg/day until relapse + NS Wijermans (2010) 333 Thal 50mg/day until relapse + + Waage (2010) 357 Thal 200mg/day until relapse NS NS Beksac (2011) 122 Thal 100mg/day continuously NS NS Ludwig (2010) 124 Thal 200mg/day + IFN until relapse + NS Morgan (2012) 327 Thal mg/day until relapse + NS Ludwig et al. IMWG consensus on maintenance in MM 2012;119:3003
8 The biggest problem with thalidomide maintenance is toxicity Up to 80% of patients discontinue or dose-reduce thalidomide due to toxicity NCIC Stewart et al. Blood 2013 THAL-PRED associated with significant worsening of QOL: Physical: 34% vs. 21% worsened (p=0.03) Role: 29% vs. 17% (p=0.04) Cognitive: 54% vs. 41% (p=0.01) Global: 40% vs. 26% (p=0.01)
9 The biggest problem with thalidomide maintenance is toxicity Up to 80% of patients discontinue or dose-reduce thalidomide due to toxicity NCIC Stewart et al. Blood 2013 THAL-PRED associated with significant worsening of QOL: Physical: 34% vs. 21% worsened (p=0.03) Role: 29% vs. 17% (p=0.04) Cognitive: 54% vs. 41% (p=0.01) Global: 40% vs. 26% (p=0.01)
10 Patients with high risk disease, particularly del(17p), have particularly poor outcomes with thalidomide maintenance High risk ifish: t(4;14), t(14;20), t(14;16), gain(1q), del(1p32), del(17p) Morgan et al. Blood 2012;119:7-15
11 Summary: Thalidomide maintenance Pros: Convenient (oral) PFS improvement Not myelosuppressive Cons: OS benefit unclear Cumula>ve toxici>es (neuropathy 50%) most cannot tolerate >1-2 years Not useful (may even be harmful!) in high risk disease (17pdel) Costly $1650/month at 100mg/ day Can improve quality of response (bezer as consolida>on?)
12 Maintenance Therapy in MM Phase 3 trials Post- transplant o Thalidomide 7 trials (thalidomide +/- steroids) o Lenalidomide IFM (consolida.on and maintenance) CALGB o Bortezomib Hovon MM 65/GMMG- HD4 (btz alone) Following non- transplant therapy o Thalidomide o 4 RCTs comparing MPT vs MP used thalidomide maintenance o CEMSG thal + IFN o MRC IX thal alone o Lenalidomide MM- 015 (MPR- R) o Bortezomib GIMEMA (VMPT- VT)
13 Lenalidomide maintenance
14 CALGB IFM N= 460 Patients 70 yo Patients < 65yo N= 614 I80% IMiD (35% Len, 45%Thal) 41% bortezomib Induction 90% VAD or bortezomib-dex 25% received additional DCEP Non-progressive after 1x ASCT Non-progressive after 1-2x ASCT Randomization Randomization Placebo (N=231) maintenance Primary Endpoint PFS/TTP Lenalidomide 10 mg/d until relapse (N=229) Lenalidomide consolidation 25 mg days1-21 q28d x 2 Placebo (N=307) maintenance Lenalidomide mg/d until relapse (N=307) McCarthy et al. NEJM 2012;366: Attal et al. NEJM 2012;366:
15 Lenalidomide Maintenance Post- ASCT Effect on PFS/EFS CALGB IFM mo 42 mo 21.9 mo 24 mo 24 mo Progression Free Survival (PFS) Event Free Survival (EFS) McCarthy P et al., N Engl J Med 2012;366: Attal M., et al., N Engl J Med 2012;366:
16 Lenalidomide Maintenance Post- ASCT Overall Survival Benefit? CALGB IFM deaths in len arm, 39 deaths in placebo arm Median follow-up 28 mos, P=0.018 Median followup 30 mos, P=NS McCarthy et al. NEJM 2012;366: Attal M et al. NEJM 2012;366:
17 MM- 015 Phase 3 trial in non- ASCT pa.ents N = 459 Double-Blind Treatment Phase Open-Label Extension Phase Cycles (28-day) 1-9 Cycles 10+ RANDOMISATION MPR-R M: 0.18 mg/kg, days 1-4 P: 2 mg/kg, days 1-4 R: 10 mg/day po, days 1-21 MPR M: 0.18 mg/kg, days 1-4 P: 2 mg/kg, days 1-4 R: 10 mg/day po, days 1-21 MP M: 0.18 mg/kg, days 1-4 P: 2 mg/kg, days 1-4 PBO: days 1-21 Continuous Lenalidomide Treatment 10 mg/day days 1-21 Placebo Placebo Disease Progression Lenalidomide (25 mg/day) +/- Dexamethasone Stratified by age ( 75 vs > 75 years) and stage (ISS I/II vs III) M, melphalan; P, prednisone; R, lenalidomide; PBO, placebo; po, orally; ISS, International Staging System.
18 MP vs MPR vs MPR- R (Len maintenance) in non- ASCT pa.ents PFS OS MPR is no bezer than MP however, the addi>on of R maintenance prolongs PFS (landmark from start of maintenance: median PFS from 7 to 26 mos (HR 0.34) Palumbo et al., NEJM 2012;366:
19 Are the toxicities of maintenance lenalidomide worth it? Grade 3-4 Toxicity IFM CALGB Len Placebo Len Placebo Neutropenia 51% 18% 45% 15% Thrombocytopenia 14% 7% 14% 4% Febrile neutropenia 1% <1% 5% 1% Documented Infection 13% 5% 6% 3% VTE 6% 2% 1% 0% Discontinuation due to toxicity Second primary malignancies 27% 15% 6% 3% 8% 4% 7.8% 2.6% 1/3 of pa.ents on lenalidomide maintenance in MM- 015 trial needed GCSF support Attal et al. NEJM 2012;366: McCarthy et al. NEJM 2012;366:
20 Is the risk of SPM cumulative over time? Incidence Rate (per 100 Patient Years) SEER Age-specific IR of invasive cancers in ages = All Patients (N=3,846) 12 (N=697) 18 (N=450) 24 (N=313) 36 (N=130) Treatment Duration (Months) Incidence Rate Dimopoulos et al. Blood 2012;119:2764
21 Early survival benefit balanced with median >me to diagnosis of SPM (MDS/AML 28 mos; solid tumors 15 mos) Should we truncate maintenance to 1-2 years? McCarthy et al. NEJM 2012;366:
22 Would high risk disease benefit from lenalidomide maintenance? Risk group No. Endpoint Therapy Present Absent Reference t(4;14) 28/102 Median OS LD in RRMM 18 mos 23 mos MM /158 Median OS LD in RRMM 9 mos 15 mos IFM 152/355 Median PFS Lenalidomide maintenance 27 mos 42 mos IFM Del(17p) 12/118 Median OS LD in RRMM 4 mos 23 mos MM % Median PFS Lenalidomide maintenance 29 mos 42 mos IFM 2005 Unfavorable FISH 16/84 3- y OS LD 77% 86% Mayo 21/ y OS LD 76% 91% E4A03 Although lenalidomide improves the outcomes of cytogene>cally high risk MM, outcomes are consistently worse than low/standard risk pa>ents. Bergsagel Blood 2013;121:884
23 Does maintenance lead to drug resistence? MM-015 Double-Blind Treatment Phase Open-Label Extension Phase Cycles (28-day) 1-9 Cycles 10+ RANDOMISATION MPR-R M: 0.18 mg/kg, days 1-4 P: 2 mg/kg, days 1-4 R: 10 mg/day po, days 1-21 MPR M: 0.18 mg/kg, days 1-4 P: 2 mg/kg, days 1-4 R: 10 mg/day po, days 1-21 MP M: 0.18 mg/kg, days 1-4 P: 2 mg/kg, days 1-4 PBO: days 1-21 Continuous Lenalidomide Treatment 10 mg/day days 1-21 Placebo Placebo Disease Progression Lenalidomide (25 mg/day) +/- Dexamethasone Stratified by age ( 75 vs > 75 years) and stage (ISS I/II vs III) M, melphalan; P, prednisone; R, lenalidomide; PBO, placebo; po, orally; ISS, International Staging System.
24 Does maintenance lead to drug resistence? MM- 015 trial Received 2 nd line therapy MPR-R (N = 81) MPR (N = 117) MP (N = 127) Patients receiving Lenalidomide containing regimens Time from 2 nd to 3 rd line after a Lenalidomide regimen Time from 2 nd to 3 rd line after a Bortezomib regimen Time from 2 nd to 3 rd line after Other regimens 24 (30%) 68 (58%) 92 (72%) 18 mos 23 mos 18 mos 14 mos 16 mos 12 mos 13 mos 8 mos 10 mos Patients relapsing on Len maintenance had similar second-line treatment duration compared with those relapsing while on placebo Maintenance lenalidomide may NOT lead to more aggressive or resistant relapse Palumbo et al. ASH 2012 abstract 944
25 Does maintenance lead to drug resistence? MM- 015 trial Received 2 nd line therapy MPR-R (N = 81) MPR (N = 117) MP (N = 127) Patients receiving Lenalidomide containing regimens Time from 2 nd to 3 rd line after a Lenalidomide regimen Time from 2 nd to 3 rd line after a Bortezomib regimen Time from 2 nd to 3 rd line after Other regimens 24 (30%) 68 (58%) 92 (72%) 18 mos 23 mos 18 mos 14 mos 16 mos 12 mos 13 mos 8 mos 10 mos Patients relapsing on Len maintenance had similar second-line treatment duration compared with those relapsing while on placebo Maintenance lenalidomide may NOT lead to more aggressive or resistant relapse Palumbo et al. ASH 2012 abstract 944
26 Could we achieve the same without maintenance and reserving lenalidomide for relapse? Resistent relapse Randomiza>on Post- transplant A B Len maintenance TTP 46 mos Nothing Nothing TTP 27 mos Relapse TTP? Len for relapse TTP 11 mos Which approach leads to longer survival? Route A may use up 2 therapies Nonresponders
27 Summary: Lenalidomide maintenance Pros: Convenient (oral) Impressive PFS improvement May not predispose to resistance Cons: OS benefit unclear Hematologic toxici>es Risk of Second Primary Malignancies (SPM) Not as effec>ve in high risk disease Costly $11,000/month using 10mg/day dosing (plus cost of GCSF $225 per 300ug vial)
28 Maintenance Therapy in MM Phase 3 trials Post- transplant o Thalidomide 7 trials (thalidomide +/- steroids) o Lenalidomide IFM (consolida>on and maintenance) CALGB o Bortezomib Hovon MM 65/GMMG- HD4 (btz alone) Following non- transplant therapy o Thalidomide o 4 RCTs comparing MPT vs MP used thalidomide maintenance o CEMSG thal + IFN o MRC IX thal alone o Lenalidomide MM- 015 (MPR- R) o Bortezomib GIMEMA (VT following VMP- VT) PETHEMA (VP vs VT)
29 HOVON- 65/GMMG- HD4 Trial: bortezomib induc.on and maintenance N=827 3 x VAD Randomiza.on 3 x PAD Bortezomib 1.3 mg/ m 2 IV Doxorubicin 9 mg/m 2 Dex 40 mg CAD + GCSF CAD + GCSF MEL PBSCT In GMMG 2 nd MEL PBSCT Thalidomide maintenance 50 mg/day for 2 years Allogeneic Tx MEL PBSCT In GMMG 2 nd MEL PBSCT Bortezomib maintenance 1.3 mg/m 2 / 2 weeks for 2 years Landmark analysis 12 mos aeer randomiza.on showed both PFS and OS benefit to Btz arm Sonneveld P et al. JCO 2012;30:
30 HOVON-65/GMMG-HD4 Trial: PFS and OS in del(17p) N=65 PFS 26.2 mos 3 yr OS 69% PFS 12 mos 3 yr OS 17% Arm A VAD induction, ASCT, thal maintenance Arm B PAD induction, ASCT, bortezomib maintenance Typically, PFS post- ASCT for del(17p) is 8 mos, OS 15 mos Neben et al. Blood Jan 26;119(4):940-8
31 HOVON-65/GMMG-HD4 Trial: Renal Failure OS Arm B - btz Arm A - thal Renal Failure (creatinine >2mg/dL) Months since randomisation Sonneveld et al. JCO (2012) 30:
32 GIMEMA: VMPT-VT versus VMP in non-asct elderly patients Patients > 65yo (median=71) Randomization Phase III N= 511 Arm A Induction VMPT (Thal 50mg/day) Arm B Induction VMP maintenance VT x 2 years bortezomib 1.3mg/m 2 d1,15 thalidomide 50mg/d continuous Nothing Palumbo et al. JCO 2010;28:5101
33 VMPT-VT versus VMP in the elderly Median follow- up: 47.2 mos VMPT-VT VMP P Median PFS Not reached 27.3 mos < year OS 59.3% 45.9% yr landmark analysis after induction: 4-year OS 64.6% 49.7% year OS from relapse 40.7% 50.2% NS Median dura>on of VT maintenance 23.8 mos 7% grade 3-4 neuropathy 12% discon>nued due to AEs Palumbo et al. ASH 2012, abstract 200
34 Summary: Bortezomib maintenance Pros: OS benefit strongest of all novel agents à even in high risk disease No apparent risk of secondary malignancies and minimally myelosuppressive Cons: Limited data Inconvenient Neuropathy risk Costly - $1180 per dose (average BSA)
35 Conclusions: so what should we do? S>ll debatable, but Thalidomide maintenance appears passé but may s>ll have a role if used appropriately limited to 1 year, low- dose, in low- risk disease, if VGPR incorporated into consolida>on (?) Consider maintenance lenalidomide in non- high risk pa>ents 18 mos PFS benefit is s>ll remarkable, even if you don t believe there is an OS benefit Need to inform the pa>ent about risks, including SPM Dura>on unclear reasonable to aim for 1-2 years
36 Conclusions: so what should we do? Consider maintenance bortezomib in pa>ents who have the most to lose with progressive disease High risk 17p dele>on Renal failure Consolida.on may be the bezer route shorter dura>on, greater compliance, fewer longterm toxici>es (lower SPM risk?), likely less expensive (?) Most compelling evidence for VTD thus far but limited data More studies needed
37 Thank- you! PMCC Myeloma Group Dr. Donna Reece Dr. Chris>ne Chen Dr. Suzanne Trudel Dr. Vishal Kukre> Dr. Rodger Tiedemann Clinical trials manager - Giovanni Piza Transplant coordinator - Andrew Winter
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationMaintenance therapy after autologous transplantation
Maintenance therapy after autologous transplantation Sonja Zweegman MD PhD Department of Hematology Amsterdam The Netherlands Disclosures Research funding from Celgene, Takeda and Janssen Participation
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More informationAutologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy
Autologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy Donna E. Reece, M.D. Princess Margaret Hospital Toronto, ON CANADA 10 December 2011 ASCT in Myeloma..
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationContinuous Therapy as a Standard of Care CON. JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France
Continuous Therapy as a Standard of Care CON JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France 1 In France and in the IFM all debates 2 In France and in the IFM all debates
More informationConsolidation and Maintenance therapy
University of Salamanca Consolidation and Maintenance therapy María-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain Disclosure form MVM has served as member of advisory boards or received
More informationMYELOMA MAINTENANCE BEST PRACTICES:
MYELOMA MAINTENANCE BEST PRACTICES: POST THERAPY & POST TRANSPLANT Aric Hall, MD Assistant Professor University of Wisconsin Hospital and Clinics INTRODUCTION MYELOMA Clonal plasma cell malignancy leading
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationCurrent Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.
Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene
More informationMichel Delforge Belgium. New treatment options for multiple myeloma
Michel Delforge Belgium New treatment options for multiple myeloma Progress in the treatment of MM over the past 40 years 1962 Prednisone + melphalan 1990s Supportive care 1999 First report on thalidomide
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationMultiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
More informationManagement of Multiple
Management of Multiple Myeloma in the Elderly Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France INSERM U837, équipe 3 IRCL, CHRU, Lille, France IMPRT Institut de Médecine Prédictive
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationOncology Highlights ASCO 2011 MULTIPLE MYELOMA
Oncology Highlights ASCO 211 MULTIPLE MYELOMA July 211 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist, Mayo Clinic Arizona Disclosures
More informationTiming of Transplant for Multiple Myeloma
Timing of Transplant for Multiple Myeloma Wenming CHEN Beijing Chaoyang Hospital Capital Medical University Multiple myeloma resrarch center of Beijing Initial Approach to Treatment of Myeloma Nontransplantation
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationTreatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice
Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice Friday, December 2, 2016 San Diego, California This program is supported by educational grants from
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationInduction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationNew Treatment Paradigms in Transplant-Eligible Myeloma Patients
New Treatment Paradigms in Transplant-Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Turkey, March 1 st 2013 NEW TREATMENT PARADıGM
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationMAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA. Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health
MAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health Disclosures I have no significant conflicts of interest to disclose.
More informationIl trattamento del Mieloma su stratificazione di rischio: è oggi possibile?
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationVI. Autologous stem cell transplantation and maintenance therapy
Hematological Oncology Hematol Oncol 2013; 31 (Suppl. 1): 42 46 Published online in Wiley Online Library (wileyonlinelibrary.com).2066 Supplement Article VI. Autologous stem cell transplantation and maintenance
More informationMultiple Myeloma: Diagnosis and Primary Treatment
Multiple Myeloma: Diagnosis and Primary Treatment George Somlo, MD City of Hope Comprehensive Cancer Center NCCN.org For Clinicians NCCN.org/patients For Patients Educational Objectives Discuss considerations
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationMyeloma and renal failure Future directions. Karthik Ramasamy
Myeloma and renal failure Future directions Karthik Ramasamy Overview Historical perspective & Background Drug interventions & trials OPTIMAL Trial Future directions Burden of disease Upto 40% of newly
More informationMeu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin
Meu paciente realizou um TACTH na 1a linha, e agora? Tandem, Manutenção, Consolidação? Marcelo C Pasquini, MD, MS Medical College of Wisconsin Post Auto HCT Options for MM Maintenance Lenalidomide vs.
More informationPosttransplantation Maintenance Therapy and Optimal Frontline Therapy in Myeloma
CONTROVERSIES AND UPDATES IN MULTIPLE MYELOMA Posttransplantation Maintenance Therapy and Optimal Frontline Therapy in Myeloma Donna E. Reece 1 1 Princess Margaret Hospital, Toronto, ON One of the major
More informationWhat New in Hematopoietic Stem Cell Transplantation? Joseph M. Tuscano, M.D. UCD Cancer Center
What New in Hematopoietic Stem Cell Transplantation? Joseph M. Tuscano, M.D. UCD Cancer Center 1 JOSEPH TUSCNO, MD WHAT S NEW IN HEMATOPOEITIC STEM CELL TRANSPLANTATION? RELEVANT FINANCIAL RELATIONSHIPS
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationChoosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
More informationMultiple Myeloma: Approach to the Elderly
Multiple Myeloma: Approach to the Elderly Peter Anglin MD, FRCPC, MBA Stronach Regional Cancer Centre Newmarket, ON PMH Myeloma Day May 12, 2017 Peter Anglin MD Disclosures Speakers Bureau Advisory Boards
More informationStem Cell Transplant for Myeloma: The New Landscape
Stem Cell Transplant for Myeloma: The New Landscape Sergio A. Giralt, MD Chief, Adult Bone Marrow Transplant Service Division of Hematologic Oncology Department of Medicine Memorial Sloan-Kettering Cancer
More informationUK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook
UK Myeloma Research Alliance Myeloma XII study (ACCoRD): Augmented Conditioning & Consolidation in Relapsed Disease UK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook Sponsor ID: Pending
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationRole of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape
Role of Stem Cell Transplantation in Multiple Myeloma: The Changing Landscape Simrit Parmar, MD MDACC Houston, TX, USA Why Transplant in the Era of Novel Therapy? Safe (TRM
More informationTransplant in MM patients: Early versus late. Mario Boccadoro. Barcelona
Transplant in MM patients: Early versus late Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Transplant in MM patients: Early versus
More informationMULTIPLE MYELOMA. TREATMENT in 2017 MC. VEKEMANS
MULTIPLE MYELOMA TREATMENT in 2017 MC. VEKEMANS NATURAL HISTORY of MM WHO SHOULD BE TREATED? DEFINITION MGUS Smouldering Multiple Myeloma Symptomatic Multiple Myeloma Monoclonal component (blood and/or
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationDevelopments in the Treatment of Multiple Myeloma Kenneth C. Anderson, M.D.
Developments in the Treatment of Multiple Myeloma Kenneth C. Anderson, M.D. Kraft Family Professor of Medicine Harvard Medical School Director, Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer
More informationOvercoming Current Challenges in the Management of De Novo and Relapsed/Refractory Multiple Myeloma
Overcoming Current Challenges in the Management of De Novo and Relapsed/Refractory Multiple Myeloma George Somlo M.D. City of Hope Comprehensive Cancer Center The Cause 1 Myeloma: Clinical Features Bone
More informationOptimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice
REVIEW Korean J Intern Med 2016;31:809-819 Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice Ho Sup Lee 1 and Chang-Ki Min 2 1 Department of Internal Medicine,
More informationTraditional Therapies for Waldenstrom s Macroglobulinemia. Christine Chen Princess Margaret Cancer Centre Toronto, Canada May 2014
Traditional Therapies for Waldenstrom s Macroglobulinemia Christine Chen Princess Margaret Cancer Centre Toronto, Canada May 2014 Jeff Atlin (1953-2014) Standard treatment options Single drug therapies
More informationDisclosures. Consultancy, Research Funding and Speakers Bureau: Celgene Corporation, Millennium, Onyx, Cephalon
Pomalidomide With or Without Low-dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Outcomes in Patients Refractory to Lenalidomide and Bortezomib Ravi Vij 1, Paul G. Richardson
More informationIs Myeloma Curable in 2012?
Is Myeloma Curable in 2012? YES Cure is living long enough to die of another cause April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist,
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationHow to treat a newly diagnosed young patient with multiple myeloma
How to treat a newly diagnosed young patient with multiple myeloma J.F. San Miguel University of Salamanca, Spain Department of Haematology University of Salamanca Cancer Research Centre Disclosures for
More informationPlasma cells in bone marrow. Treatment of Multiple Myeloma Novel Approaches. Approach to Progressive MM. Approach to Initial Therapy
Treatment of Multiple Myeloma ovel Approaches Plasma cells in bone marrow Donna E. Reece, M.D. Princess Margaret Hospital Toronto, 21 ctober 25 Adhesion Molecules and Growth Factors in Multiple Myeloma
More informationDisclosures for Alessandra Larocca, MD
Disclosures for Alessandra Larocca, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria No relevant conflicts of interest to declare No relevant conflicts of interest
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationAutologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011
Autologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011 Significant impact of ASCT before the availability of novel agents? Randomized trials: Single
More informationRisk of Second Primary Malignancies (SPMs) Following. Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3
ASH2933 Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)
More informationMultiple Myeloma: Treatment Updates
Faculty Disclosures Multiple Myeloma: Treatment Updates No conflicts of interest to disclose Andy Kurtzweil, PharmD, BCOP Pharmacy Clinical Team Leader, Hem/Onc/BMT University of Minnesota Medical Center,
More informationMULTIPLE MYELOMA AFTER AGE OF 80 YEARS
MULTIPLE MYELOMA AFTER AGE OF 80 YEARS C. Hulin CHU Nancy, France Intergroupe Francophone du Myelome (IFM) Epidemiology SEER Program between 1990-2004: 17 330 MM cases, 51% 70 y and 20% 80 y. Brenner et
More informationReviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto)
MULTIPLE MYELOMA Updated March 2017 by Doreen Ezeife, PGY-5 resident, University of Calgary Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist,
More informationMultiple Myeloma: Update from ASH. Kenneth C. Anderson, M.D. Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Harvard Medical School
Multiple Myeloma: Update from ASH Kenneth C. Anderson, M.D. Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Harvard Medical School Integration of Novel Therapy Into Myeloma Management
More informationInternational Myeloma Foundation Patient and Family Seminar
International Myeloma Foundation Patient and Family Seminar Vienna, Austria May 6 th, 2006 New Development in Diagnosis & Treatments Brian G.M. Durie, M.D., Chairman International Myeloma Foundation What
More informationOncologist. The. Academia Pharma Intersect: Myelomas. Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
The Oncologist Academia Pharma Intersect: Myelomas Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective HEINZ LUDWIG, a MERAL BEKSAC, b JOAN BLADÉ, c MARIO BOCCADORO,
More informationStudy Objectives: GMMG MM5
Study Objectives: GMMG MM5 1.) Demonstration of non-inferiority of VCD induction therapy compared to PAd induction therapy with respect to response rate (very good partial remission or better; response
More informationManagement of Multiple Myeloma
Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Lenalidomide (Revlimid) for Multiple Myeloma October 22, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Lenalidomide (Revlimid) for Multiple Myeloma October 22, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationOncologist. The. Academia Pharma Intersect: Myelomas. Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective
The Oncologist Academia Pharma Intersect: Myelomas Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective HEINZ LUDWIG, a MERAL BEKSAC, b JOAN BLADÉ, c JAMIE CAVENAGH,
More informationMultiple myeloma. November 24, 2017 at Vientiane, Laos
Multiple myeloma November 24, 2017 at Vientiane, Laos Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi, Mahidol University, Thailand Multiple myeloma
More informationIncidence: ~4/100,000 persons/year Prevalence: 60,000 patients (Europe) Incidence increases with age: 80% of patients > 60 years (rare in < 35 y.
Multiple myeloma Second most common hematological malignancy Incidence: ~4/100,000 persons/year Prevalence: 60,000 patients (Europe) Incidence increases with age: 80% of patients > 60 years (rare in
More informationComorbidities in Multiple Myeloma
Comorbidities in Multiple Myeloma Michel Delforge, MD, PhD University Hospital Leuven Leuven, Belgium COMy, Bangkok 12 may 2014 Comy Meeting, Bangkok, 12 may 2014 Disclosures Advisory board: Janssen,
More informationAcademia Pharma Intersect: Myelomas
The Oncologist Academia Pharma Intersect: Myelomas European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses HEINZ LUDWIG, a HERVÉ AVET-LOISEAU, b JOAN BLADÉ, c
More informationPhase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Phase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Jatin J Shah, MD, Sheeba Thomas, MD, Donna Weber, MD, Michael Wang, MD, Raymond Alexanian, MD, Robert
More informationMultiple Myeloma: Miami, FL Current Treatment Paradigms and Future Directions December 18, 2009
Welcome to Master Class for Oncologists Miami, FL December 18, 29 Session 5: 11: AM - 11:45 AM Multiple Myeloma: Current Treatment Paradigms and Future Directions Speaker: Kenneth C. Anderson, MD Chief,
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Bortezomib as first line induction prior to melphalan and autologous stem cell transplantation (ASCT) in untreated symptomatic multiple myeloma patients suitable
More informationone patient advocacy group (Myeloma Canada) the submitter (Cancer Care Ontario Hematology Disease Site Group) the manufacturer (Janssen Inc.
perc noted that the pcodr Economic Guidance Panel s estimates of the use of bortezomib in both pre- ASCT and post-asct settings when compared with standard induction therapy and observation-only maintenance
More information